NADINE
Nanosystems for the early Diagnosis of Neurodegenerative diseases
| Coordinatore | DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
| Nazionalità Coordinatore | Denmark [DK] |
| Sito del progetto | http://www.FP7nadine.eu |
| Totale costo | 11˙702˙928 € |
| EC contributo | 9˙000˙000 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2009-LARGE-3 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-09-01 - 2015-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
DK (KONGENS LYNGBY) | coordinator | 1˙267˙662.00 |
| 2 |
INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
FR (PARIS) | participant | 1˙243˙927.60 |
| 3 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: Valhallavaegen 79 contact info |
SE (STOCKHOLM) | participant | 714˙072.00 |
| 4 |
FLUIGENT SA
Organization address
address: RUE DU FAUBOURG SAINT JACQUES 29 contact info |
FR (PARIS) | participant | 711˙567.00 |
| 5 |
UNIVERSITE PARIS-SUD
Organization address
address: RUE GEORGES CLEMENCEAU 15 contact info |
FR (ORSAY) | participant | 670˙613.50 |
| 6 |
FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA
Organization address
address: CAMPUS DE LA UAB EDIFICI Q ICN2 contact info |
ES (BELLATERRA (BARCELONA)) | participant | 664˙892.25 |
| 7 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 579˙000.00 |
| 8 |
DIAGNOSWISS SA
Organization address
address: ZI LES ILETTES SECTEUR 4 contact info |
CH (MONTHEY) | participant | 564˙182.60 |
| 9 |
UNIVERZITA PARDUBICE
Organization address
address: Studentska 95 contact info |
CZ (PARDUBICE) | participant | 453˙067.20 |
| 10 |
"USTAV MAKROMOLEKULARNI CHEMIE AV CR, v.v.i."
Organization address
address: HEYROVSKEHO NAM. 2 contact info |
CZ (PRAHA 6) | participant | 437˙124.00 |
| 11 |
UNIVERSITAETSKLINIKUM ESSEN
Organization address
address: HUFELANDSTRASSE 55 contact info |
DE (ESSEN) | participant | 336˙562.00 |
| 12 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 331˙191.25 |
| 13 |
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
DE (GOETTINGEN) | participant | 223˙200.00 |
| 14 |
"MORAVIAN-BIOTECHNOLOGY, SPOL.SRO"
Organization address
address: BOHUSLAVA MARTINU 90 contact info |
CZ (BRNO STRED) | participant | 213˙879.70 |
| 15 |
RAMBOLL DANMARK A/S
Organization address
address: HANNEMANNS ALLEE 53 contact info |
DK (KOBENHAVN) | participant | 212˙250.00 |
| 16 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA 1 E contact info |
FI (Kuopio) | participant | 180˙559.60 |
| 17 |
ASSOCIATION POUR LA RECHERCHE ET LE DEVELOPPEMENT DES METHODES ET PROCESSUS INDUSTRIELS - ARMINES
Organization address
address: Boulevard Saint-Michel 60 contact info |
FR (PARIS) | participant | 144˙889.38 |
| 18 | KOBENHAVNS UNIVERSITET | DK | participant | 51˙360.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal “metabiomarker” signatures. Progress, however, is hindered by low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the present project is to apply these progresses in biotechnology, nanoparticle synthesis, and nano-instrumentation to the development of fully integrated lab-on chip instruments able to perform elaborate multimodal biomarker analysis on a routine basis and at the ultrasensitive level required to allow minimally invasive tests. In particular, we aim at overcoming a major bottleneck on the path to this objective, which was identified in a previous project in the “HEALTH” priority: no satisfactory solution currently exists to bridge the several orders of magnitude between the nanoscale volumes at which ultrasensitive new generation sensors operate, and the often millilitre volumes of samples in which the molecules of interest must be found. For this, we shall combine innovations in pre-concentration, micro and nanofluidics, self-assembly, micro-nanofabrication, and nanodetection. The project will develop a generic, multipurpose, platform of compatible enabling technologies, and integrate them into devices. In order to maximize impact and societal benefit, the project will be validated on an application of major interest for health, namely the early detection of biomarkers for neurodegenerative diseases (including Alzheimer), with special emphasis on subtyping of these diseases for improved treatment strategies. The consortium includes a multidisciplinary group of technology developers, three leading biomedical groups in clinical neuroscience for definition of specifications and end-user pre-clinical validation, and three research-oriented SMEs in biotechnology, nanosensing and microfluidics.'
Introduzione (Teaser)
The rate of discovery of biomarkers for disease is accelerating at unprecedented speed. However, progress in diagnosis is frequently hindered by an inability to detect molecular biomarkers at the low levels often predominant in body fluids.